Synthesis and Characterization of Curcumin Analogues with Enhanced Antidiabetic, Anti-Inflammatory, and Anticancer Activity
International Journal of Drug Delivery Technology · 30.04.2026 · 16 (23s)
DOI: 10.25258/ijddt.16.23s.23 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 30.04.2026. Verfasst von Pooja G. Swami und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione), a polyphenolic phytoconstituent derived from the rhizomes of Curcuma longa Linn., has long been recognized as a pharmacologically versatile scaffold exhibiting antidiabetic, anti-inflammatory, anticancer, and antioxidant properties. Despite its broad therapeutic potential, the clinical translation of curcumin has been severely hampered by its inherent physicochemical limitations, including extremely poor aqueous solubility (11 ng/mL at physiological pH), rapid metabolic conjugation, photodegradation, and limited systemic bioavailability. To overcome these shortcomings and augment pharmacological efficacy, a series of eight structurally diverse curcumin analogues (CA-1 through CA-8) was designed, synthesized, and comprehensively characterized in the present investigation. The synthetic strategy involved Claisen–Schmidt condensation of substituted aldehydes with acetylacetone or its congeners, followed by selective Knoevenagel condensation, O-alkylation, and ester bioisostere incorporation as warranted by the structural target. All synthesized compounds were purified by column chromatography and recrystallization, and characterized by UV-Vis, FTIR, ¹H-NMR, ¹³C-NMR, and high-resolution mass spectrometry (HRMS). The compounds were evaluated for in vitro antidiabetic activity (α-amylase and α-glucosidase inhibition), anti-inflammatory activity (albumin denaturation inhibition and COX-2 inhibitory assay), and anticancer activity (MTT assay on MCF-7 breast cancer and HeLa cervical carcinoma cell lines). Molecular docking studies against PDB targets 3L4W (α-glucosidase), 1EQG (COX-2), and 3ERT (estrogen receptor-α) corroborated the in vitro findings. ADME profiling using SwissADME and pkCSM platforms confirmed drug-likeness of selected analogues. Among the analogues, CA-3 (3,4-dimethoxy-substituted) and CA-7 (fluorinated aryl congener) demonstrated the most potent multitarget activity with IC₅₀ values superior to curcumin and comparable to reference standards. The study establishes a rational structure–activity relationship framework and identifies CA-3 and CA-7 as promising lead candidates warranting further pre-formulation and pharmacokinetic investigation.
Zitieren
APA
Swami, P. G., Bagali, R. S., Narute, A. S., Bhagat, J., Pathak, N., Madan, S., Saxena, S., & Walia, R. (2026). Synthesis and Characterization of Curcumin Analogues with Enhanced Antidiabetic, Anti-Inflammatory, and Anticancer Activity. International Journal of Drug Delivery Technology, 16(23s). https://doi.org/10.25258/ijddt.16.23s.23
Vancouver
Swami PG, Bagali RS, Narute AS, Bhagat J, Pathak N, Madan S, et al. Synthesis and Characterization of Curcumin Analogues with Enhanced Antidiabetic, Anti-Inflammatory, and Anticancer Activity. International Journal of Drug Delivery Technology. 2026;16(23s). doi:10.25258/ijddt.16.23s.23
BibTeX
@article{Swami2026,
author = {Swami, Pooja G. and Bagali, Rajkumar S and Narute, Ashok Sarjerao and Bhagat, Jenish and Pathak, Nidhi and Madan, Swati and Saxena, Shikha and Walia, Ramanpreet},
title = {Synthesis and Characterization of Curcumin Analogues with Enhanced Antidiabetic, Anti-Inflammatory, and Anticancer Activity},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {23s},
doi = {10.25258/ijddt.16.23s.23}
}
EUVIMED